30 March 2021
Rymarz Zdort advised ExploRNA Therapeutics in the process of an equity investment that involved a subscription for shares in ExploRNA Therapeutics by the fund Black Forest SICAV-SIF (owned by Michał Sołowow) and the provision of funds for the expansion of the former’s operations.
ExploRNA Therapeutics is a biotech spin-off company of the University of Warsaw, which develops ground-breaking mRNA modification technologies paving the way for new therapeutic applications of mRNA in medicine, such as COVID-19 vaccines.
Black Forest SICAV-SIF is an investment fund supporting scientific and technological advancements achieved by both Polish and foreign companies. Active in a number of industries and sectors, Black Forest’s net asset value has now exceeded EUR 4.1 billion. Products manufactured by its companies are sold throughout the world (in more than 60 countries, in six continents).
The investment by Black Forest SICAV-SIF will allow ExploRNA Therapeutics to develop and implement an ambitious research program focusing on the use of mRNA for therapeutic purposes and enhancing the company’s research potential.
12 February 2026
Five recognised practices are not only a source of pride for us, but also confirmation that we consistently deliver value to our clients, which is also reflected in global rankings. Recognised prac...
28 January 2026
We are pleased to announce that we advised the Grant Thornton Advisors platform on the addition of Grant Thornton Polska to the multinational platform that it formed in 2025 with support from a group ...
9 January 2026
Mergermarket has published its global and regional rankings of legal advisors in the field of mergers and acquisitions for 2025 – Global and Regional M&A Rankings 2025 – Legal Advisors. This annua...
30 December 2025
We are pleased to announce that we advised GKSD S.r.l. (“GKSD”) and Gruppo San Donato (“GSD”) on the acquisition of a 27.78% stake in the share capital of American Heart of Poland S.A. (“AHP”), AHP Lo...
22 December 2025
We are pleased to announce that we advised Synthos S.A. on signing an agreement with ORLEN S.A. to sell 100% of its shares in S54. S54 is a company that is building a new butadiene extraction unit in ...
19 December 2025
We are pleased to announce that our team advised the founders of Unilogo Robotics, one of the fastest growing Polish companies in the industrial robotics industry, in the process of procuring two inve...
17 December 2025
We are pleased to announce that our team advised Dalkia Polska sp. z o.o., a company belonging to the French EDF Group (Électricité de France), on the acquisition of 100% of the shares in Edison Next ...
13 December 2025
We are pleased to announce that we advised Ocean Winds in connection with securing approximately EUR 2 billion in project financing from a consortium of international financial institutions (including...
12 December 2025
We are pleased to announce that we advised BEST S.A. on the establishment of the bond issuance programme for up to PLN 1 billion and the first issue of unsecured bonds under such programme with a valu...
5 December 2025
We are pleased to announce that we advised Bank Polska Kasa Opieki S.A. in connection with arranging a senior preferred and senior non-preferred bond issue programme of up to PLN 50 million establishe...
25 November 2025
With our support, Dutch fund Pluralis B.V. ("Pluralis") has entered into an investment agreement with Polskie Towarzystwo Wspierania Przedsiębiorczości S.A. ("PTWP"). The agreement covers the trans...
24 November 2025
We are pleased to announce that in October 2025, the ad hoc Arbitration Tribunal based in Stockholm issued a ruling in the case of Orlen S.A. (formerly PGNiG S.A.) v. Gazprom PJSC and Gazprom export L...
7 November 2025
We are delighted to announce that, in the latest edition of IFLR1000 2025, our firm has once again been recognised as one of the leading law firms in Poland – this time with exceptional results across...
